Management Change/Compensation (Form 8-K)

On January 18, 2026, the Board of Directors (the "Board") of Hyperscale Data, Inc. (the "Company"), based on the recommendation of the Nominating and Governance Committee of the Board, appointed Michael "Mickey" Lorber to the Board, effective January 19, 2026. Mr. Lorber was also appointed to the Audit Committee of the Board (the "Audit Committee") and as Chairman of the Audit Committee.

Mr. Lorber served as the Audit Partner at Baker Tilly US, LLP in their San Diego, California office, from November 2020 until his retirement in May 2024. Prior to Baker Tilly, Mr. Lorber was an Audit Partner at Squar Milner, LLP, in their San Diego, California office, between January 2005 and October 2020. Previously, Mr. Lorber served as the Chief Financial Officer for Visijet, Inc., Chief Financial Officer at Sagient Research Systems, Inc., Vice President - Finance and Chief Financial Officer for Promark Sports, Inc., Vice President - Finance and Chief Financial Officer for Tomahawk II, Inc., and Vice President and Chief Financial Officer for Lidak Pharmaceuticals (currently Avanir Pharmaceuticals). Mr. Lorber received his Bachelor of Science in Accounting from the University of Illinois at Champaign-Urbana. Mr. Lorber has been a Certified Public Accountant since 1979 and currently holds his CPA license from the State of California. Mr. Lorber was elected to serve on the Board because of his decades of experience as an expert on U.S. GAAP financial accounting, internal controls and procedures, Securities and Exchange Commission disclosure reporting and audit oversight.

There is no arrangement or understanding between Mr. Lorber and any other persons pursuant to which Mr. Lorber was selected as a director. There are no family relationships between Mr. Lorber and any director, executive officer or person nominated or chosen by the Company to become a director or executive officer of the Company within the meaning of Item 401(d) of Regulation S-K ("Regulation S-K"). Mr. Lorber is not a party to any transaction, or any proposed transaction, required to be disclosed pursuant to Item 404(a) of Regulation S-K.

In conjunction with Mr. Lorber's appointment, the Board increased the standard annual compensation for the Company's non-employee directors to $55,000, with each of the lead independent director and the Chairman of the Audit Committee receiving an additional $10,000 per annum. Further, the Board granted Mr. Lorber options to purchase 250,000 shares of the Company's Class A Common Stock at an exercise price of $0.297 per share for a term of ten (10) years from the date of the option grant. Fifty percent (50%) of these options shall vest on the date that Company obtains the approval therefor by its stockholders and 50% of which shall vest monthly beginning February 1, 2026 and will be exercisable upon receipt of approval therefor by the NYSE American and the Company's stockholders.

In connection with the appointment of Mr. Lorber to the Board, the Board increased the size of the Board from six to seven members.